灵霉素
荟萃分析
随机对照试验
严格标准化平均差
萧条(经济学)
抗抑郁药
临床终点
重性抑郁障碍
心理学
医学
临床试验
致幻剂
精神科
临床心理学
内科学
认知
焦虑
经济
宏观经济学
作者
Sipan Haikazian,David Chen‐Li,Danica E. Johnson,Farhan Fancy,Anastasia Levinta,Muhammad Ishrat Husain,Rodrigo B. Mansur,Roger S. McIntyre,Joshua D. Rosenblat
标识
DOI:10.1016/j.psychres.2023.115531
摘要
The aim of this review was to determine the effect of psilocybin on depressive symptoms in patients diagnosed with life-threatening illnesses or major depressive disorder. Systematic searches were conducted to search for randomized clinical trials and open-label trials that evaluated depression symptoms after psilocybin therapy. Data was pooled using a random-effects model. The primary outcome was the standardized mean difference (SMD) in depression severity, determined by calculating the change in depression ratings from baseline to the primary endpoint in the psilocybin arm versus the control arm. The literature search yielded 1734 studies, and 13 studies (n = 686) were included in either qualitative and/or quantitative analyses. The meta-analysis included 9 studies (pooled n = 596) and yielded a large effect size in favour of psilocybin (SMD = -0.78; p<0.001). Risk ratios for response and remission were large and significant in favour of psilocybin. A review of open-label trials showed robust decreases in depressive symptoms following psilocybin administration. These findings provide preliminary evidence for antidepressant efficacy with psilocybin-assisted psychotherapy, however, further studies are needed to evaluate safety and efficacy and to optimize treatment protocols.
科研通智能强力驱动
Strongly Powered by AbleSci AI